DK2314629T4 - Rekombinant produktion af blandinger af antistoffer - Google Patents

Rekombinant produktion af blandinger af antistoffer Download PDF

Info

Publication number: DK2314629T4
Authority: DK; Denmark
Prior art keywords: mixtures; antibodies; nucleic acid; light chain; host cell
Prior art date: 2002-07-18

Application number

DK10186063.3T

Other languages

English (en)

Other versions

DK2314629T3 (da

Inventor

Berkel Patricius Hendrikus Van

Ronald Hendrik Peter Brus

Abraham Bout

Ton Logtenberg

Original Assignee

Merus Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-18

Filing date

2003-07-15

Publication date

2023-02-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43768900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2314629(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-07-15 Application filed by Merus Nv filed Critical Merus Nv

2014-01-20 Publication of DK2314629T3 publication Critical patent/DK2314629T3/da

2023-02-06 Application granted granted Critical

2023-02-06 Publication of DK2314629T4 publication Critical patent/DK2314629T4/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Hematology (AREA)
Transplantation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

DK10186063.3T 2002-07-18 2003-07-15 Rekombinant produktion af blandinger af antistoffer DK2314629T4 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US39706602P	2002-07-18	2002-07-18
EP02077953		2002-07-18
EPPCT/EP03/50201		2003-05-27
EP03764997A EP1523496B1 (en)	2002-07-18	2003-07-15	Recombinant production of mixtures of antibodies

Publications (2)

Publication Number	Publication Date
DK2314629T3 DK2314629T3 (da)	2014-01-20
DK2314629T4 true DK2314629T4 (da)	2023-02-06

Family

ID=43768900

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK03764997.7T DK1523496T3 (da)	2002-07-18	2003-07-15	Rekombinant fremstilling af blanding af antistoffer
DK10186063.3T DK2314629T4 (da)	2002-07-18	2003-07-15	Rekombinant produktion af blandinger af antistoffer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK03764997.7T DK1523496T3 (da)	2002-07-18	2003-07-15	Rekombinant fremstilling af blanding af antistoffer

Country Status (14)

Country	Link
US (9)	US7262028B2 (da)
EP (2)	EP2314629B2 (da)
JP (4)	JP4836451B2 (da)
CN (3)	CN101537180B (da)
AT (1)	ATE514717T1 (da)
AU (2)	AU2003250074B2 (da)
CA (3)	CA2965865C (da)
CY (1)	CY1111886T1 (da)
DK (2)	DK1523496T3 (da)
ES (2)	ES2368733T3 (da)
NZ (1)	NZ537277A (da)
PT (2)	PT1523496E (da)
SI (1)	SI1523496T1 (da)
WO (1)	WO2004009618A2 (da)

Families Citing this family (310)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6783980B2 (en) *	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
KR100470180B1 (ko)	1995-06-15	2005-02-04	크루셀 홀란드 비.브이.	유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
DK0979281T3 (da) *	1997-05-02	2005-11-21	Genentech Inc	Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US20030207346A1 (en) *	1997-05-02	2003-11-06	William R. Arathoon	Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en)	1997-05-02	2011-05-31	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
US8236561B2 (en) *	1999-04-15	2012-08-07	Crucell Holland B.V.	Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) *	1999-04-15	2007-11-20	Crucell Holland B.V.	Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1 (en) *	1999-04-15	2005-02-15	Crucell Holland B.V.	Recombinant protein production in a human cell
US20050164386A1 (en) *	1999-04-15	2005-07-28	Uytdehaag Alphonsus G.	Overexpression of enzymes involved in post-translational protein modifications in human cells
US7521220B2 (en) *	1999-11-26	2009-04-21	Crucell Holland B.V.	Production of vaccines
US7192759B1 (en) *	1999-11-26	2007-03-20	Crucell Holland B.V.	Production of vaccines
US7658924B2 (en) *	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US7521053B2 (en) *	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
CN100347306C (zh) *	2001-10-29	2007-11-07	克鲁塞尔荷兰公司	生产具有预定的翻译后修饰的蛋白质的方法和手段
EP2314629B2 (en)	2002-07-18	2022-11-16	Merus N.V.	Recombinant production of mixtures of antibodies
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
EP1563100B1 (en) *	2002-11-01	2013-04-24	Iris Molecular Diagnostics, Inc.	Displacement sandwich immuno-pcr
GB0230201D0 (en) *	2002-12-27	2003-02-05	Domantis Ltd	Retargeting
CA2512647C (en)	2003-01-07	2013-10-08	Symphogen A/S	Method for manufacturing recombinant polyclonal proteins
DE602004021095D1 (de) *	2003-01-21	2009-06-25	Chugai Pharmaceutical Co Ltd	Verfahren zum screening der leichten kette eines antikörpers
DE602004027483D1 (de) *	2003-05-23	2010-07-15	Crucell Holland Bv	Herstellung von rekombinanten igm in den per.c6 zellen
WO2004106375A1 (en)	2003-05-30	2004-12-09	Merus Biopharmaceuticals B.V. I.O.	Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
EP1508576A1 (en) *	2003-08-20	2005-02-23	Crucell Holland B.V.	Efficient production of IgA in recombinant mammalian cells
AU2005205412B2 (en)	2004-01-20	2011-08-11	Merus N.V.	Mixtures of binding proteins
AU2011218688B2 (en) *	2004-05-27	2013-01-10	Crucell Holland B.V.	Binding molecules capable of neutralizing rabies virus and uses thereof
WO2005118644A2 (en) *	2004-05-27	2005-12-15	Crucell Holland B.V.	Binding molecules capable of neutralizing rabies virus and uses thereof
US7973134B2 (en)	2004-07-07	2011-07-05	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
PL1787126T3 (pl) *	2004-07-20	2010-03-31	Symphogen As	Sposób charakteryzowania poliklonalnej linii komórkowej
MX2007000644A (es)	2004-07-20	2007-03-28	Symphogen As	Anticuerpo policlonal recombinante anti-rhesus d y metodos de fabricacion.
US7935790B2 (en)	2004-10-04	2011-05-03	Cell Singaling Technology, Inc.	Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
EP1815028B1 (en) *	2004-11-03	2011-10-26	Iris Molecular Diagnostics, Inc.	Microbubbles for affinity separation
CN103146808A (zh) *	2004-11-03	2013-06-12	意力速分子诊断股份有限公司	均相分析物检测
US7807789B2 (en)	2004-12-21	2010-10-05	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
CN101198698B (zh)	2005-03-31	2014-03-19	中外制药株式会社	通过调节多肽缔合制备多肽的方法
CA2603264C (en) *	2005-04-08	2017-03-21	Chugai Seiyaku Kabushiki Kaisha	Antibody substituting for function of blood coagulation factor viii
ES2417065T3 (es)	2005-04-26	2013-08-05	Trion Pharma Gmbh	Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
WO2007027906A2 (en)	2005-08-31	2007-03-08	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20070111237A1 (en) *	2005-09-14	2007-05-17	Maurizio Zanetti	Process for identifying antigenized antibodies using ribosome cell free expression system
AU2012201010B2 (en) *	2005-10-21	2015-01-22	Genzyme Corporation	Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
ES2417147T3 (es) *	2005-10-21	2013-08-06	Revo Biologics, Inc.	Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
DE102005054628A1 (de) *	2005-11-16	2007-05-24	Cevec Pharmaceuticals Gmbh	Verfahren zur Herstellung von permanenten humanen Zelllinien
JP2009518320A (ja)	2005-12-05	2009-05-07	シュムフォウエンアクティーゼルスカブ	抗オルトポックスウイルス組換えポリクローナル抗体
US20120208824A1 (en)	2006-01-20	2012-08-16	Cell Signaling Technology, Inc.	ROS Kinase in Lung Cancer
WO2007094472A1 (ja) *	2006-02-17	2007-08-23	Atsuo Sekiyama	生体負荷の指標剤および生体負荷の測定方法
ES2965283T3 (es)	2006-03-15	2024-05-28	Alexion Pharma Inc	Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
CN104761637B (zh)	2006-03-31	2021-10-15	中外制药株式会社	调控抗体血液动力学的方法
EP2009101B1 (en)	2006-03-31	2017-10-25	Chugai Seiyaku Kabushiki Kaisha	Antibody modification method for purifying bispecific antibody
US7939636B2 (en)	2006-08-11	2011-05-10	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in c-Src signaling pathways
ES2378407T3 (es)	2006-09-01	2012-04-12	Therapeutic Human Polyclonals, Inc.	Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos
KR101503540B1 (ko)	2006-09-05	2015-03-17	알렉시온 파마슈티칼스, 인코포레이티드	항체 매개된 신경병증의 치료를 위한 방법과 조성물
MX2009005414A (es)	2006-12-05	2009-06-01	Crucell Holland Bv	Formulaciones liquidas de anticuerpo antirrabico.
NZ597466A (en)	2007-03-01	2013-08-30	Symphogen As	Recombinant anti-epidermal growth factor receptor antibody compositions
EP1972639A3 (en)	2007-03-07	2008-12-03	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20090068684A1 (en)	2007-03-26	2009-03-12	Cell Signaling Technology, Inc.	Serine and threoninephosphorylation sites
NL1033696C2 (nl) *	2007-04-16	2008-10-20	Friesland Brands Bv	Aan melk ontleende antigeen-specifieke antilichamen, werkwijzen voor het bereiden en gebruik ervan.
EP2145902A3 (en)	2007-04-19	2010-09-29	Peter Hornbeck	Tyrosine phosphorylation sites and antibodies specific for them
EP1983003A3 (en)	2007-04-19	2009-03-11	Peter Hornbeck	Tyrosine phosphorylation sites and antibodies specific for them
US7977462B2 (en)	2007-04-19	2011-07-12	Cell Signaling Technology, Inc.	Tyrosine phosphorylation sites
US20090053831A1 (en)	2007-05-01	2009-02-26	Cell Signaling Technology, Inc.	Tyrosine phosphorylation sites
HRP20100640T1 (hr) *	2007-05-25	2010-12-31	Symphogen A/S	Postupak proizvodnje rekombinantnog poliklonskog proteina
WO2009002380A2 (en) *	2007-06-26	2008-12-31	The Trustees Of The University Of Pennsylvania	Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
EP3741851A1 (en)	2007-10-18	2020-11-25	Cell Signaling Technology, Inc.	Translocation and mutant ros kinase in human non-small cell lung carcinoma
US20090203043A1 (en)	2007-11-21	2009-08-13	Peter Hornbeck	Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
JO2913B1 (en) *	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2252893B1 (en) *	2008-02-21	2013-10-23	Iris International, Inc.	Method for early determination of recurrence after therapy for prostate cancer
EP2098536A1 (en)	2008-03-05	2009-09-09	4-Antibody AG	Isolation and identification of antigen- or ligand-specific binding proteins
WO2009126306A2 (en)	2008-04-10	2009-10-15	Cell Signaling Technology, Inc.	Compositions and methods for detecting egfr mutations in cancer
CA2722348A1 (en) *	2008-04-23	2009-10-29	Symphogen A/S	Methods for manufacturing a polyclonal protein
JP5646457B2 (ja)	2008-04-29	2014-12-24	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリン及びその使用
EP3002299A1 (en)	2008-06-03	2016-04-06	AbbVie Inc.	Dual variable domain immunoglobulins and uses thereof
RU2731084C2 (ru)	2008-06-27	2020-08-28	Мерюс Н.В.	Продуцирующие антитела млекопитающие, не являющиеся человеком
US8148088B2 (en)	2008-07-18	2012-04-03	Abgent	Regulation of autophagy pathway phosphorylation and uses thereof
EP2331577B1 (en)	2008-08-29	2017-06-07	Symphogen A/S	Recombinant anti-epidermal growth factor receptor antibody compositions
EP2159291A1 (en)	2008-09-01	2010-03-03	Agendia B.V.	Means and method for determining tumor cell percentage in a sample
EP2389392A1 (en) *	2009-01-26	2011-11-30	Genmab A/S	Methods for producing mixtures of antibodies
EP2393927B1 (en)	2009-02-09	2014-12-31	MorphoSys AG	Production of oligoclonal mixtures of immunoglobulins in single cells
JP5979877B2 (ja)	2009-02-12	2016-08-31	セル・シグナリング・テクノロジー・インコーポレイテツド	ヒト癌における変異ｒｏｓ発現
TW201613969A (en) *	2009-03-05	2016-04-16	Abbvie Inc	IL-17 binding proteins
AU2010245011B2 (en) *	2009-04-27	2015-09-03	Oncomed Pharmaceuticals, Inc.	Method for making heteromultimeric molecules
LT2975051T (lt)	2009-06-26	2021-07-12	Regeneron Pharmaceuticals, Inc.	Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
CN102638971B (zh)	2009-07-08	2015-10-07	科马布有限公司	动物模型及治疗分子
US8623358B2 (en)	2009-08-29	2014-01-07	Abbvie Inc.	Therapeutic DLL4 binding proteins
RU2016105962A (ru)	2009-12-04	2018-11-23	Дженентек, Инк.	Мультиспецифические антитела, аналоги антител, композиции и способы
US9796788B2 (en)	2010-02-08	2017-10-24	Regeneron Pharmaceuticals, Inc.	Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en)	2010-02-08	2013-02-21	Regeneron Pharmaceuticals, Inc.	Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
HRP20151188T4 (hr) *	2010-02-08	2021-10-01	Regeneron Pharmaceuticals, Inc.	Miš sa zajedničkim lakim lancem
US20120021409A1 (en) *	2010-02-08	2012-01-26	Regeneron Pharmaceuticals, Inc.	Common Light Chain Mouse
EP2542582A4 (en)	2010-03-02	2013-12-04	Abbvie Inc	THERAPEUTIC PROTEINS LINKING TO DLL4
CA2796633C (en) *	2010-04-23	2020-10-27	Genentech, Inc.	Production of heteromultimeric proteins
AU2011252883B2 (en)	2010-05-14	2015-09-10	Abbvie Inc.	IL-1 binding proteins
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
KR102306967B1 (ko)	2010-08-02	2021-10-01	리제너론 파아마슈티컬스, 인크.	Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
US8735546B2 (en)	2010-08-03	2014-05-27	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
US20120101108A1 (en)	2010-08-06	2012-04-26	Cell Signaling Technology, Inc.	Anaplastic Lymphoma Kinase In Kidney Cancer
AU2011290480B2 (en)	2010-08-16	2015-07-30	Novimmune S.A.	Methods for the generation of multispecific and multivalent antibodies
PH12013500337A1 (en)	2010-08-26	2017-08-23	Abbvie Inc	Dual variable domain immunoglobulins and uses thereof
WO2012031273A2 (en)	2010-09-03	2012-03-08	Stem Centrx, Inc.	Novel modulators and methods of use
KR101962483B1 (ko)	2010-11-17	2019-03-29	추가이 세이야쿠 가부시키가이샤	혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
WO2012121775A2 (en)	2010-12-21	2012-09-13	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
MY161859A (en)	2011-01-03	2017-05-15	Avm Biotechnology Llc	Personalized production of biologics and method for reprogramming somatic cells
LT2738259T (lt)	2011-02-25	2020-03-10	Regeneron Pharmaceuticals, Inc.	Adam6 pelės
WO2012122512A1 (en)	2011-03-10	2012-09-13	Hco Antibody, Inc.	Recombinant production of mixtures of single chain antibodies
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
UA117901C2 (uk)	2011-07-06	2018-10-25	Ґенмаб Б.В.	Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
PT3865581T (pt) *	2011-08-05	2024-10-04	Regeneron Pharma	Murganhos da cadeia leve universal humanizada
AU2012311286B2 (en)	2011-09-19	2018-07-26	Kymab Limited	Antibodies, variable domains and chains tailored for human use
SI3485903T1 (sl)	2011-09-23	2023-02-28	Mereo Biopharma 5, Inc.	Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
CA2791109C (en)	2011-09-26	2021-02-16	Merus B.V.	Generation of binding molecules
HRP20240230T1 (hr)	2011-10-11	2024-04-26	F. Hoffmann - La Roche Ag	Poboljšani sklop bispecifičnih protutijela
KR20140082824A (ko)	2011-10-17	2014-07-02	리제너론 파아마슈티컬스, 인크.	제한된 면역글로불린 중쇄 마우스
BR112014009810A2 (pt)	2011-10-24	2017-04-25	Abbvie Inc	imunoligantes biespecíficos dirigidos contra tnf e il-17
EP2771360A1 (en)	2011-10-24	2014-09-03	AbbVie Inc.	Immunobinders directed against sclerostin
EP2773664A1 (en)	2011-11-01	2014-09-10	Bionomics, Inc.	Anti-gpr49 antibodies
EP2773373B1 (en)	2011-11-01	2018-08-22	Bionomics, Inc.	Methods of blocking cancer stem cell growth
JP2014533247A (ja)	2011-11-01	2014-12-11	バイオノミクスインコーポレイテッド	抗体および癌を治療する方法
AU2012332593B2 (en)	2011-11-01	2016-11-17	Bionomics, Inc.	Anti-GPR49 antibodies
PT3527070T (pt)	2011-12-20	2025-12-19	Regeneron Pharma	Murganhos de cadeia leve humanizada
US10233424B2 (en)	2011-12-22	2019-03-19	Elwha Llc	Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
US8962315B2 (en)	2011-12-22	2015-02-24	Elwha Llc	Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US9175072B2 (en)	2011-12-22	2015-11-03	Elwha Llc	Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US10745468B2 (en)	2011-12-22	2020-08-18	Kota Biotherapeutics, Llc	Compositions and methods for modified B cells expressing reassigned biological agents
UY34556A (es)	2011-12-30	2013-07-31	Abbvie Inc	Dominio variable dual de inmunoglobulinas y sus usos
US9120870B2 (en)	2011-12-30	2015-09-01	Abbvie Inc.	Dual specific binding proteins directed against IL-13 and IL-17
US9550830B2 (en)	2012-02-15	2017-01-24	Novo Nordisk A/S	Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
MX353278B (es) *	2012-03-06	2018-01-05	Regeneron Pharma	Raton con cadena ligera comun.
HK1200271A1 (en)	2012-03-16	2015-08-07	瑞泽恩制药公司	Mice that produce antigen-binding proteins with ph-dependent binding characteristics
DK2825036T3 (da)	2012-03-16	2018-07-16	Regeneron Pharma	Histidinmanipulerede letkædeantistoffer og genetisk modificerede gnavere til generering heraf
US20140013456A1 (en)	2012-03-16	2014-01-09	Regeneron Pharmaceuticals, Inc.	Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
KR102213535B1 (ko)	2012-03-16	2021-02-08	리제너론 파마슈티칼스 인코포레이티드	pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
US10251377B2 (en)	2012-03-28	2019-04-09	Kymab Limited	Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en)	2012-05-17	2013-11-20	Kymab Ltd	Multivalent antibodies and in vivo methods for their production
ES2655842T3 (es)	2012-04-18	2018-02-21	Cell Signaling Technology, Inc.	EGFR y ROS1 en el cáncer
DK2838918T3 (da)	2012-04-20	2019-08-12	Merus Nv	Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
KR102023401B1 (ko) *	2012-05-10	2019-11-04	바이오아트라, 엘엘씨	다중-특이적 모노클로날 항체
EP3912464A1 (en)	2012-06-12	2021-11-24	Regeneron Pharmaceuticals, Inc.	Humanized non-human animals with restricted immunoglobulin heavy chain loci
EP3632462A1 (en)	2012-07-06	2020-04-08	Genmab B.V.	Dimeric protein with triple mutations
US11180572B2 (en)	2012-07-06	2021-11-23	Genmab B.V.	Dimeric protein with triple mutations
TW201402608A (zh)	2012-07-12	2014-01-16	Abbvie Inc	Ｉｌ－１結合蛋白質
CN102851338A (zh)	2012-07-25	2013-01-02	苏州康宁杰瑞生物科技有限公司	利用电荷排斥作用制备同二聚体蛋白混合物的方法
ES2456823B1 (es) *	2012-09-21	2015-01-27	Consejo Superior De Investigaciones Científicas (Csic)	Método de producción de repertorios complejos de moléculas recombinantes
PL2900694T3 (pl) *	2012-09-27	2018-12-31	Merus N.V.	Dwuswoiste przeciwciała igg jako aktywatory komórek t
AU2013337775B2 (en)	2012-11-01	2017-03-30	Abbvie Inc.	Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
EP2915819B1 (en) *	2012-11-05	2019-08-14	Zenyaku Kogyo Kabushikikaisha	Antibody and antibody composition production method
BR112015012014A2 (pt)	2012-12-04	2017-07-11	Abbvie Inc	proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
US20140219913A1 (en)	2012-12-28	2014-08-07	Abbvie, Inc.	Dual Specific Binding Proteins Having a Receptor Sequence
US9856319B2 (en)	2012-12-28	2018-01-02	Abbvie Inc.	Monovalent binding proteins
AU2013372331A1 (en)	2013-01-10	2015-07-23	Genmab B.V.	Human IgG1 Fc region variants and uses thereof
EP2946016A4 (en) *	2013-01-15	2016-11-23	Univ California	ADENOVIRES AND THEIR USE
MY185881A (en)	2013-02-20	2021-06-14	Regeneron Pharma	Non-human animals with modified immunoglobulin heavy chain sequences
JP2016519568A (ja) *	2013-03-13	2016-07-07	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	共通軽鎖のマウス
EP2970459A2 (en)	2013-03-15	2016-01-20	AbbVie Inc.	Dual specific binding proteins directed against il-1beta and il-17
MX2015013170A (es)	2013-03-15	2016-07-26	Abbvie Inc	Proteinas de union especificas duales dirigidas contra tnf alpha.
US9788534B2 (en)	2013-03-18	2017-10-17	Kymab Limited	Animal models and therapeutic molecules
US11707056B2 (en)	2013-05-02	2023-07-25	Kymab Limited	Animals, repertoires and methods
US9783593B2 (en)	2013-05-02	2017-10-10	Kymab Limited	Antibodies, variable domains and chains tailored for human use
KR102363220B1 (ko)	2013-07-05	2022-02-15	젠맵 에이/에스	인간화 또는 키메라 cd3 항체
US10208125B2 (en)	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
CN105764922B (zh)	2013-09-27	2020-07-17	中外制药株式会社	多肽异源多聚体的制备方法
CA2925723A1 (en)	2013-10-01	2015-04-09	Kymab Limited	Animal models and therapeutic molecules
MX2016004420A (es)	2013-10-06	2017-03-31	Abbvie Inc	Proteinas de union especificas duales dirigidas contra los receptores de células inmunes y autoantígenos de señalización de tlr.
WO2015084883A2 (en)	2013-12-02	2015-06-11	Abbvie, Inc.	Compositions and methods for treating osteoarthritis
DK3105250T3 (da)	2014-02-10	2020-09-28	Igm Biosciences Inc	Multispecifikke iga-bindingsmolekyler
SMT202500020T1 (it)	2014-02-28	2025-03-12	Merus Nv	Anticorpo che lega erbb-2 ed erbb-3
EP3786186A1 (en)	2014-02-28	2021-03-03	Merus N.V.	Antibodies that bind egfr and erbb3
CN106164092A (zh)	2014-03-21	2016-11-23	瑞泽恩制药公司	表现不同结合特征的vl抗原结合蛋白
CN106255410B (zh)	2014-03-21	2020-01-10	瑞泽恩制药公司	产生单结构域结合蛋白的非人动物
DK3126384T3 (da)	2014-04-01	2021-01-18	Adimab Llc	Multispecifikke antistofanaloger omfattende en fælles letkæde, og fremgangsmåder til deres fremstilling og anvendelse
IL292311A (en)	2014-04-03	2022-06-01	Igm Biosciences Inc	J-chain qualified
AU2015240599B2 (en)	2014-04-04	2020-11-19	Bionomics, Inc.	Humanized antibodies that bind LGR5
HRP20231139T1 (hr)	2014-05-06	2024-01-05	F. Hoffmann - La Roche Ag	Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
MY186389A (en) *	2014-05-13	2021-07-22	Univ Pennsylvania	Compositions comprising aav expressing dual antibody constructs and uses thereof
EP3169706B1 (en)	2014-07-11	2019-12-04	Genmab A/S	Antibodies binding axl
AR101262A1 (es)	2014-07-26	2016-12-07	Regeneron Pharma	Plataforma de purificación para anticuerpos biespecíficos
TWI701435B (zh)	2014-09-26	2020-08-11	日商中外製藥股份有限公司	測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh)	2014-09-26	2020-08-01	日商中外製藥股份有限公司	中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
US20170304460A1 (en)	2014-10-01	2017-10-26	Medimmune, Llc	Method of conjugating a polypeptide
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
WO2016110576A1 (en)	2015-01-08	2016-07-14	Genmab A/S	Bispecific antibodies against cd3 and cd20
CN110655582B (zh)	2015-01-08	2022-12-16	江苏康宁杰瑞生物制药有限公司	具有共同轻链的双特异性抗体或抗体混合物
JP7179464B2 (ja)	2015-01-20	2022-11-29	アイジーエムバイオサイエンシズインコーポレイテッド	腫瘍壊死因子（ｔｎｆ）スーパーファミリー受容体結合分子およびその使用
SG11201707144VA (en)	2015-03-04	2017-09-28	Igm Biosciences Inc	Cd20 binding molecules and uses thereof
US11111314B2 (en)	2015-03-19	2021-09-07	Regeneron Pharmaceuticals, Inc.	Non-human animals that select for light chain variable regions that bind antigen
US11142587B2 (en)	2015-04-01	2021-10-12	Chugai Seiyaku Kabushiki Kaisha	Method for producing polypeptide hetero-oligomer
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CA2991805A1 (en)	2015-07-10	2017-01-19	Genmab A/S	Axl-specific antibody-drug conjugates for cancer treatment
AU2016293942B2 (en)	2015-07-10	2022-06-16	Merus B.V.	Human CD3 binding antibody
PL3322727T3 (pl)	2015-07-15	2026-05-11	Genmab A/S	Humanizowane lub chimeryczne przeciwciała cd3
MX2018002493A (es) *	2015-08-27	2018-06-07	Crystal Bioscience Inc	Animal transgenico para la produccion de anticuerpos que tienen una cadena ligera comun.
CA2999284C (en)	2015-09-30	2023-06-13	Igm Biosciences A/S	Binding molecules with modified j-chain
US11639389B2 (en)	2015-09-30	2023-05-02	Igm Biosciences, Inc.	Binding molecules with modified J-chain
WO2017069628A2 (en)	2015-10-23	2017-04-27	Merus N.V.	Binding molecules that inhibit cancer growth
WO2017110980A1 (ja)	2015-12-25	2017-06-29	中外製薬株式会社	増強された活性を有する抗体及びその改変方法
SG11201803989WA (en)	2015-12-28	2018-06-28	Chugai Pharmaceutical Co Ltd	Method for promoting efficiency of purification of fc region-containing polypeptide
US11414477B2 (en)	2016-01-27	2022-08-16	Medimmune, Llc	Methods for preparing antibodies with a defined glycosylation pattern
JP7082604B2 (ja)	2016-03-21	2022-06-08	マレンゴ・セラピューティクス，インコーポレーテッド	多重特異性および多機能性分子ならびにその使用
KR20180138205A (ko)	2016-03-22	2018-12-28	바이오노믹스 리미티드	항-lgr5 단클론성 항체의 투여
ES3055961T3 (en)	2016-04-28	2026-02-17	Chugai Pharmaceutical Co Ltd	Antibody-containing preparation
JP7301540B2 (ja)	2016-05-26	2023-07-03	チールーピュージェットサウンドバイオセラピューティクスコーポレイション	抗体の混合物
UA128304C2 (uk)	2016-07-14	2024-06-05	Ґенмаб А/С	Мультиспецифічне антитіло до cd40 і cd137
CN109415444B (zh)	2016-07-29	2024-03-01	中外制药株式会社	显示增加的备选fviii辅因子功能活性的双特异性抗体
EP3509637B1 (en)	2016-09-06	2024-11-27	Chugai Seiyaku Kabushiki Kaisha	Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
CN109983033B (zh)	2016-09-23	2023-10-31	美勒斯公司	调节细胞表达的生物活性的结合分子
JP7277363B2 (ja)	2016-11-01	2023-05-18	ジェンマブビー．ブイ．	ポリペプチド変異体およびその使用
US11447789B2 (en)	2016-12-01	2022-09-20	Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence	Production in plants of ricin antibodies that bind to ricin B chain
KR20190113870A (ko) *	2017-02-02	2019-10-08	메르크 파텐트 게엠베하	항체 도메인의 바람직한 페어링
AU2018218345B2 (en)	2017-02-10	2025-04-03	Genmab B.V.	Polypeptide variants and uses thereof
WO2018151820A1 (en)	2017-02-16	2018-08-23	Elstar Therapeutics, Inc.	Multifunctional molecules comprising a trimeric ligand and uses thereof
PT3592769T (pt)	2017-03-09	2024-07-31	Genmab As	Anticorpos contra pd-l1
US11780925B2 (en)	2017-03-31	2023-10-10	Merus N.V.	ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
CA3058342A1 (en)	2017-03-31	2018-10-04	Merus N.V.	Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
EP3603670A4 (en)	2017-03-31	2021-03-10	Public University Corporation Nara Medical University	MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BLOOD CLOG FACTOR IX ANOMALY WITH A MULTI-SPECIFIC ANTIGIBINDING MOLECULAR FUNCTION OF BLOOD CLOTHING FACTOR VIII
SG11201908772TA (en)	2017-03-31	2019-10-30	Genmab Holding B V	Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
US12195551B2 (en)	2017-05-17	2025-01-14	Merus N.V.	Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
AR111963A1 (es)	2017-05-26	2019-09-04	Univ California	Método y moléculas
WO2018222901A1 (en)	2017-05-31	2018-12-06	Elstar Therapeutics, Inc.	Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CA3068929A1 (en)	2017-07-06	2019-01-10	Merus N.V.	Binding molecules that modulate a biological activity expressed by a cell
EA202090005A1 (ru)	2017-07-06	2020-06-18	Мерус Н.В.	Антитела, модулирующие биологическую активность, проявляемую клеткой
MX2020000055A (es)	2017-07-06	2020-08-06	Merus Nv	Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
GB201710984D0 (en) *	2017-07-07	2017-08-23	Kymab Ltd	Cells, vertebrates, populations & methods
IL272159B2 (en)	2017-08-04	2026-03-01	Genmab As	PD-L1 and CD137 binding agents and their use
SI3665198T1 (sl)	2017-08-09	2025-06-30	Merus N.V.	Protitelesa, ki vežejo egfr in cmet
JP6496095B1 (ja)	2017-09-29	2019-04-03	中外製薬株式会社	血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤
TW202600611A (zh)	2017-11-01	2026-01-01	日商中外製藥股份有限公司	生物活性降低之抗體變異體與同功型
JP7317016B2 (ja) *	2017-12-19	2023-07-28	スロゼンオペレーティング，インコーポレイテッド	抗ｌｒｐ５／６抗体及び使用方法
US11773171B2 (en)	2017-12-19	2023-10-03	Surrozen Operating, Inc.	WNT surrogate molecules and uses thereof
WO2019139987A1 (en)	2018-01-09	2019-07-18	Elstar Therapeutics, Inc.	Calreticulin binding constructs and engineered t cells for the treatment of diseases
MA51666A (fr)	2018-01-24	2020-12-02	Genmab Bv	Variants polypeptidiques et leurs utilisations
TWI890481B (zh)	2018-02-09	2025-07-11	日商小野藥品工業股份有限公司	雙特異性抗體
CR20250347A (es)	2018-03-12	2025-09-23	Genmab As	ANTICUERPOS QUE SE UNEN A 5T4 (Divisional 2020-0463)
EP3765516A2 (en)	2018-03-14	2021-01-20	Elstar Therapeutics, Inc.	Multifunctional molecules and uses thereof
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
WO2019182910A1 (en) *	2018-03-19	2019-09-26	Elwha Llc	Compositions and methods for modified b cells expressing reassigned biological agents
SG11202009036YA (en)	2018-03-30	2020-10-29	Merus Nv	Multivalent antibody
AU2019264217B2 (en)	2018-05-03	2026-03-05	Genmab B.V.	Antibody variant combinations and uses thereof
US12275797B2 (en)	2018-06-22	2025-04-15	Genmab Holding B.V.	Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
EP3810649A1 (en)	2018-06-22	2021-04-28	Genmab A/S	Method for producing a controlled mixture of two or more different antibodies
WO2020010250A2 (en)	2018-07-03	2020-01-09	Elstar Therapeutics, Inc.	Anti-tcr antibody molecules and uses thereof
MA53123A (fr)	2018-07-13	2021-05-19	Genmab As	Thérapie à médiation par trogocytose utilisant des anticorps cd38
BR112020026432A2 (pt)	2018-07-13	2021-03-23	Genmab A/S	variante de anticorpo, ácido nucleico isolado, vetor de expressão, ácido nucleico, combinação de ácidos nucleicos, veículo de dispensação, célula hospedeira recombinante, métodos para produção de uma variante de um anticorpo, para aumentar pelo menos uma função efetora de um anticorpo parental e para tratar uma doença, anticorpo, composição, composição farmacêutica, e, variante de anticorpo para uso
US20240252635A1 (en)	2018-10-04	2024-08-01	Genmab Holding B.V.	Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
AU2019375014A1 (en)	2018-11-06	2021-05-27	Genmab A/S	Antibody formulation
WO2020141974A1 (en)	2018-12-31	2020-07-09	Merus N.V.	Truncated multivalent multimers
CN114249823A (zh)	2018-12-31	2022-03-29	美勒斯公司	混合的结合域
CA3125380A1 (en)	2019-02-18	2020-08-27	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Genetically modified non-human animals with humanized immunoglobulin locus
JP7706373B2 (ja)	2019-02-21	2025-07-11	マレンゴ・セラピューティクス，インコーポレーテッド	カルレティキュリンに結合する多機能性分子およびその使用
EP3927745A1 (en)	2019-02-21	2021-12-29	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
AU2020226904B2 (en)	2019-02-21	2025-05-01	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
GB2597851B (en)	2019-02-21	2024-05-29	Marengo Therapeutics Inc	Antibody molecules that bind to NKP30 and uses thereof
AU2020226893B2 (en)	2019-02-21	2025-02-27	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to T cell related cancer cells and uses thereof
TW202546002A (zh)	2019-03-29	2025-12-01	荷蘭商美勒斯公司	Cd3結合分子
TWI862565B (zh)	2019-04-04	2024-11-21	日商小野藥品工業股份有限公司	雙特異性抗體
MA55884A (fr)	2019-05-09	2022-03-16	Merus Nv	Domaines variants pour la multimérisation de protéines et leur séparation
US20220315661A1 (en)	2019-05-09	2022-10-06	Genmab B.V.	Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
KR20220030956A (ko)	2019-07-05	2022-03-11	오노 야꾸힝 고교 가부시키가이샤	Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
WO2021020416A1 (ja)	2019-07-30	2021-02-04	小野薬品工業株式会社	二重特異性抗体
EP3772518A1 (en)	2019-08-07	2021-02-10	Merus N.V.	Modified human variable domains
GB201912008D0 (en)	2019-08-21	2019-10-02	Cambridge Entpr Ltd	Antibody
EP4055046A1 (en)	2019-11-06	2022-09-14	Genmab B.V.	Antibody variant combinations and uses thereof
JP7773466B2 (ja)	2019-11-26	2025-11-19	シャンハイエピムアブバイオセラピューティクスカンパニーリミテッド	Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質
JP7633259B2 (ja)	2019-12-24	2025-02-19	メルスナムローゼフェンノートシャップ	ＴＧＦ－βＲＩＩ結合タンパク質
WO2021138407A2 (en)	2020-01-03	2021-07-08	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to cd33 and uses thereof
AU2020416273A1 (en)	2020-01-03	2022-07-28	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
MX2022008050A (es)	2020-01-16	2022-07-27	Genmab As	Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas.
EP4097131A1 (en)	2020-01-29	2022-12-07	Merus N.V.	Means and method for modulating immune cell engaging effects
WO2021155916A1 (en)	2020-02-04	2021-08-12	BioNTech SE	Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
EP4121456A1 (en)	2020-03-18	2023-01-25	Genmab A/S	Antibodies binding to b7h4
CN115397867A (zh) *	2020-04-13	2022-11-25	艾弗依姆恩治疗公司	Epcam抗体与car-t细胞
KR20230028242A (ko)	2020-04-24	2023-02-28	마렝고 테라퓨틱스, 인크.	T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
BR112022022730A2 (pt)	2020-05-08	2023-02-14	Genmab As	Método para tratar um linfoma não hodgkin de células b em um indivíduo humano
KR20230013030A (ko)	2020-05-21	2023-01-26	메뤼스 엔.페.	Ig-유사 분자의 생산을 위한 방법 및 수단
KR20230018439A (ko)	2020-06-02	2023-02-07	바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드	공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
EP4185388A1 (en)	2020-07-23	2023-05-31	Genmab B.V.	A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
EP4172194A1 (en)	2020-07-31	2023-05-03	CureVac SE	Nucleic acid encoded antibody mixtures
EP4192859A1 (en)	2020-08-06	2023-06-14	BioNTech SE	Binding agents for coronavirus s protein
GB2616354A (en)	2020-08-26	2023-09-06	Marengo Therapeutics Inc	Methods of detecting TRBC1 or TRBC2
KR20230074144A (ko)	2020-08-26	2023-05-26	마렝고 테라퓨틱스, 인크.	NKp30에 결합하는 항체 분자 및 이의 용도
CN116249718A (zh)	2020-08-26	2023-06-09	马伦戈治疗公司	结合至钙网蛋白的多功能性分子及其用途
EP4210746A1 (en)	2020-09-10	2023-07-19	Genmab A/S	Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
US20240034812A1 (en)	2020-09-10	2024-02-01	Genmab A/S	Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
KR20230080437A (ko)	2020-10-02	2023-06-07	젠맵 에이/에스	Ror2에 결합할 수 있는 항체 및 ror2 및 cd3에 결합하는 이중특이적 항체
US20240052050A1 (en)	2020-12-16	2024-02-15	Merus N.V.	Multispecific antibodies for the treatment of cancer
WO2022189667A1 (en)	2021-03-12	2022-09-15	Genmab A/S	Non-activating antibody variants
JP2024515591A (ja)	2021-04-08	2024-04-10	マレンゴ・セラピューティクス，インコーポレーテッド	Ｔｃｒに結合する多機能性分子およびその使用
AR125815A1 (es)	2021-05-07	2023-08-16	Genmab As	Composiciones farmacéuticas que comprenden anticuerpos biespecíficos que se unen a b7h4 y cd3
WO2022268740A1 (en)	2021-06-21	2022-12-29	Genmab A/S	Combination dosage regime of cd137 and pd-l1 binding agents
US20230109496A1 (en)	2021-09-06	2023-04-06	Genmab B.V.	Antibodies capable of binding to cd27, variants thereof and uses thereof
AR127298A1 (es)	2021-10-08	2024-01-10	Genmab As	Anticuerpos que se unen a cd30 y cd3
EP4469476A1 (en)	2022-01-25	2024-12-04	Merus N.V.	Combination therapy for the treatment of cancer
WO2023174521A1 (en)	2022-03-15	2023-09-21	Genmab A/S	Binding agents binding to epcam and cd137
CA3253038A1 (en)	2022-05-12	2023-11-16	Genmab A/S	LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
CN119365215A (zh)	2022-05-12	2025-01-24	健玛保	在组合疗法中能够结合cd27的结合剂
CN119836306A (zh)	2022-07-15	2025-04-15	费恩治疗有限公司	与cdcp1结合的抗体药物缀合物和其用途
US20250382378A1 (en)	2022-10-31	2025-12-18	Genmab A/S	Cd38 antibodies and uses thereof
JPWO2024143442A1 (da)	2022-12-27	2024-07-04
CN116333103B (zh) *	2023-02-09	2025-10-10	广州国家实验室	抗沙贝病毒属病毒的中和抗体及其制备方法和应用
CN121240884A (zh)	2023-04-05	2025-12-30	根马布股份公司	包含与cd30和cd3结合的抗体的药用组合物
US12410258B2 (en)	2023-05-12	2025-09-09	Ganmab A/S	Antibodies capable of binding to OX40, variants thereof and uses thereof
WO2025003280A1 (en)	2023-06-30	2025-01-02	Genmab A/S	Antibodies binding to fibroblast activation protein alpha and death receptor 4
WO2025056180A1 (en)	2023-09-15	2025-03-20	BioNTech SE	Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025114541A1 (en)	2023-11-30	2025-06-05	Genmab A/S	Antibodies capable of binding to ox40 in combination therapy
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025262641A1 (en)	2024-06-19	2025-12-26	Pheon Therapeutics Ltd	Antibody drug conjugates that bind cdcp1 and uses thereof
WO2026011013A1 (en)	2024-07-02	2026-01-08	Epibiologics, Inc.	Binding agents and uses thereof
WO2026050572A2 (en)	2024-08-29	2026-03-05	Marengo Therapeutics, Inc.	Multifunctional molecules binding to tcr and uses thereof
WO2026078443A1 (en)	2024-10-11	2026-04-16	Pheon Therapeutics Ltd.	Antibody drug conjugates that bind cdcp1 and uses thereof

Family Cites Families (209)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5180502A (ja)	1974-12-28	1976-07-14	Seirei Ind	Tsumejikufurikaeshikiseigyakutenkonsochi
US5179017A (en) *	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) *	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4599311A (en) *	1982-08-13	1986-07-08	Kawasaki Glenn H	Glycolytic promotersfor regulated protein expression: protease inhibitor
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
AU600885B2 (en)	1984-05-25	1990-08-30	Zymogenetics Inc.	Stable DNA constructs
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4868103A (en) *	1986-02-19	1989-09-19	Enzo Biochem, Inc.	Analyte detection by means of energy transfer
WO1988001649A1 (en)	1986-09-02	1988-03-10	Genex Corporation	Single polypeptide chain binding molecules
US4801687A (en)	1986-10-27	1989-01-31	Bioprobe International, Inc.	Monoclonal antibody purification process using protein A
US4937190A (en) *	1987-10-15	1990-06-26	Wisconsin Alumni Research Foundation	Translation enhancer
US5202238A (en) *	1987-10-27	1993-04-13	Oncogen	Production of chimeric antibodies by homologous recombination
NZ226694A (en)	1987-10-28	1994-04-27	Oncogen	Human immunoglobulin produced by recombinant dna techniques
ATE81724T1 (de) *	1987-11-09	1992-11-15	Becton Dickinson Co	Verfahren zur analyse haematopoietischer zellen in einer probe.
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
EP0768377A1 (en)	1988-09-02	1997-04-16	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
GB8909218D0 (en)	1989-04-22	1989-06-07	Medical Res Council	Improvements in or relating to enhancers
ES2062364T3 (es)	1989-06-08	1994-12-16	Wistar Inst	Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia.
WO1991000906A1 (en)	1989-07-12	1991-01-24	Genetics Institute, Inc.	Chimeric and transgenic animals capable of producing human antibodies
US5030002A (en)	1989-08-11	1991-07-09	Becton, Dickinson And Company	Method and apparatus for sorting particles with a moving catcher tube
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US5151504A (en)	1989-11-17	1992-09-29	E. R. Squibb & Sons, Inc.	Method for purification of monoclonal antibodies
ATE140027T1 (de)	1989-12-01	1996-07-15	Pharming Bv	Herstellung rekombinanter polypeptide durch rinder und transgene methoden
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
DE4006630A1 (de)	1990-03-03	1991-09-12	Behringwerke Ag	Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
CA2109602C (en)	1990-07-10	2002-10-01	Gregory P. Winter	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
JPH0568599A (ja)	1990-07-31	1993-03-23	Wistar Inst	遺伝子工学的に作られた抗体
IE76732B1 (en) *	1990-08-07	1997-11-05	Becton Dickinson Co	One step test for absolute counts
US7041871B1 (en)	1995-10-10	2006-05-09	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en)	1990-08-29	1992-03-30	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) †	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
GB9022543D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Antibody production
ES2113940T3 (es)	1990-12-03	1998-05-16	Genentech Inc	Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233769D1 (de)	1991-03-01	2009-09-24	Dyax Corp	Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE199023T1 (de)	1991-03-29	2001-02-15	Genentech Inc	Methoden zur selektion von rekombinanten wirtszellen welche hohe mengen von einem gewünschten protein exprimieren
AU662148B2 (en)	1991-04-10	1995-08-24	Scripps Research Institute, The	Heterodimeric receptor libraries using phagemids
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE4122599C2 (de)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
FI940144A7 (fi)	1991-07-15	1994-01-12	The Wellcome Foundation Ltd	Vasta-aineiden tuotanto
WO1993004169A1 (en)	1991-08-20	1993-03-04	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
AU3328493A (en)	1991-12-17	1993-07-19	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2087413A1 (en) *	1992-01-17	1993-07-18	Joseph R. Lakowicz	Fluorescent energy transfer immunoassay
US5667988A (en) *	1992-01-27	1997-09-16	The Scripps Research Institute	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US7067284B1 (en) *	1992-01-27	2006-06-27	The Scripps Research Institute	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
SE9201984D0 (sv) *	1992-06-29	1992-06-29	Pharmacia Biosensor Ab	Improvement in optical assays
AU687010B2 (en) *	1992-07-17	1998-02-19	Dana-Farber Cancer Institute	Method of intracellular binding of target molecules
ES2301158T3 (es)	1992-07-24	2008-06-16	Amgen Fremont Inc.	Produccion de anticuerpos xenogenicos.
DE4228162C1 (de)	1992-08-25	1994-01-13	Rajewsky Klaus Dr	Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
DK1975181T3 (da)	1992-10-28	2011-06-06	Genentech Inc	Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
ES2088838T3 (es)	1992-11-13	2004-01-01	Idec Pharmaceuticals Corporation	Secuencias kozak de consenso totalmente alteradas destinadas a la expresion en los mamiferos.
AU6498294A (en)	1993-04-07	1994-10-24	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Dna sequence which acts as a chromatin insulator element to protect expressed genes from (cis)-acting regulatory sequences in mammalian cells
US6838254B1 (en)	1993-04-29	2005-01-04	Conopco, Inc.	Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
WO1995007358A1 (en)	1993-07-30	1995-03-16	University Of Medicine & Dentistry Of New Jersey	Efficient gene transfer into primary lymphocytes
US5693506A (en)	1993-11-16	1997-12-02	The Regents Of The University Of California	Process for protein production in plants
US5827690A (en) *	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
AU1595195A (en)	1993-12-23	1995-07-10	Abs Global, Inc.	Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals
PT744958E (pt)	1994-01-31	2003-11-28	Univ Boston	Bancos de anticorpos policlonais
FR2717187B1 (fr)	1994-03-10	1996-05-31	Transgene Sa	Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt.
US6080560A (en)	1994-07-25	2000-06-27	Monsanto Company	Method for producing antibodies in plant cells
JPH08116978A (ja)	1994-10-18	1996-05-14	Nisshinbo Ind Inc	抗体Ｆａｂライブラリーの作製法
WO1996021012A1 (en) *	1994-12-30	1996-07-11	Planet Biotechnology, Inc.	Methods for producing immunoglobulins containing protection proteins in plants and their use
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6130364A (en)	1995-03-29	2000-10-10	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US6265150B1 (en)	1995-06-07	2001-07-24	Becton Dickinson & Company	Phage antibodies
US5783186A (en)	1995-12-05	1998-07-21	Amgen Inc.	Antibody-induced apoptosis
US5885827A (en)	1996-01-23	1999-03-23	The Regents Of The Universtiy Of California	Eukaryotic high rate mutagenesis system
US6300065B1 (en)	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US6825396B2 (en)	1996-06-12	2004-11-30	Board Of Trustees Operating Michigan State University	Methods for tissue specific synthesis of protein in eggs of transgenic hens
JP2001512560A (ja)	1996-10-08	2001-08-21	ユー―ビスイスベスローテンフェンノートシャップ	標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
GB9621113D0 (en)	1996-10-10	1996-11-27	Univ Southampton	Transgenic fish
IL130160A0 (en)	1996-12-02	2000-06-01	Univ Wake Forest	Inactivation of HIV co-receptors as therapy for HIV infection
ATE549918T1 (de)	1996-12-03	2012-04-15	Amgen Fremont Inc	Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
DK0971946T3 (da) *	1997-01-21	2006-10-30	Gen Hospital Corp	Selektion af proteiner ved anvendelse af RNA-protein-fusioner
JP2002512510A (ja)	1997-03-06	2002-04-23	インフィジェン・インコーポレーテッド	動物のクローニング方法
BR9808584A (pt)	1997-03-14	2000-05-23	Idec Pharma Corp	Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
US5830698A (en) *	1997-03-14	1998-11-03	Idec Pharmaceuticals Corporation	Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US6080912A (en)	1997-03-20	2000-06-27	Wisconsin Alumni Research Foundation	Methods for creating transgenic animals
CN1203922A (zh) *	1997-03-21	1999-01-06	三共株式会社	人源化抗人fas抗体
IL132240A0 (en)	1997-04-07	2001-03-19	Genentech Inc	Anti-vegf antibodies
US20020062010A1 (en) *	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) *	1997-05-02	2003-11-06	William R. Arathoon	Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da)	1997-05-02	2005-11-21	Genentech Inc	Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
WO1998052976A1 (en)	1997-05-21	1998-11-26	Biovation Limited	Method for the production of non-immunogenic proteins
GB2345063B (en)	1997-09-23	2002-07-24	Oxford Biomedica Ltd	Method
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
WO1999023221A2 (en)	1997-10-27	1999-05-14	Unilever Plc	Multivalent antigen-binding proteins
EP0968694B1 (en)	1997-11-26	2004-05-06	Mitsubishi Precision Co., Ltd.	Information guidance system
US6074385A (en)	1998-02-03	2000-06-13	Kiefer Corp.	Hair follicle devitalization by induced heating of magnetically susceptible particles
AU754699C (en)	1998-03-30	2003-05-15	Research Development Foundation	Corticotropin releasing factor receptor 1-deficient mice
US6413776B1 (en)	1998-06-12	2002-07-02	Galapagos Geonomics N.V.	High throughput screening of gene function using adenoviral libraries for functional genomics applications
CN1241574A (zh) *	1998-07-02	2000-01-19	中国人民解放军第四军医大学	抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体
GB9823930D0 (en) †	1998-11-03	1998-12-30	Babraham Inst	Murine expression of human ig\ locus
JP2002536968A (ja)	1999-01-29	2002-11-05	イムクローンシステムズインコーポレイティド	Ｋｄｒに特異的な抗体およびその使用
CN100457914C (zh)	1999-04-15	2009-02-04	荷兰克鲁塞尔公司	用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
EP1054018B1 (en)	1999-05-18	2009-01-28	Dyax Corp.	Fab fragment libraries and methods for their use
US6472147B1 (en)	1999-05-25	2002-10-29	The Scripps Research Institute	Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AT500848B1 (de)	1999-06-25	2008-01-15	Genentech Inc	Humanisierte anti-erbb2-antikörper
WO2001019394A2 (en)	1999-09-15	2001-03-22	Therapeutic Human Polyclonals, Inc.	Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds
US6180357B1 (en)	1999-10-08	2001-01-30	Arius Research, Inc.	Individualized patient-specific anti-cancer antibodies
AU7676300A (en) *	1999-10-12	2001-04-23	Cambridge Antibody Technology Limited	Human anti-adipocyte monoclonal antibodies and their use
AU2400500A (en)	1999-11-01	2001-05-14	Chiron Corporation	Expression vectors, transfection systems, and method of use thereof
GB9928787D0 (en) *	1999-12-03	2000-02-02	Medical Res Council	Direct screening method
CA2396029A1 (en)	1999-12-27	2001-07-05	Crucell Holland B.V.	Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope
AU2001245358A1 (en)	2000-02-29	2001-09-12	Auburn University	Production of antibodies in transgenic plastids
EP1284752A4 (en)	2000-04-26	2004-08-18	Elusys Therapeutics Inc	BISPECIFIC MOLECULES AND USES THEREOF
RU2272809C2 (ru)	2000-05-16	2006-03-27	Томас Джефферсон Юниверсити	Специфичные в отношении вируса бешенства нейтрализующие моноклональные антитела человека и нуклеиновые кислоты и связанные с ними способы
MXPA02012867A (es)	2000-06-29	2003-09-05	Abbott Lab	Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
CN1334343A (zh) *	2000-07-14	2002-02-06	中国医学科学院肿瘤医院肿瘤研究所	抑制肿瘤生长的新抗体、其衍生物及其应用
EP1184458A1 (en)	2000-08-28	2002-03-06	U-BISys B.V.	Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
EP1188771A1 (en)	2000-09-15	2002-03-20	U-BISys B.V.	Libraries of human heavy chain variable fragments in a functional format
US7737258B2 (en)	2000-10-18	2010-06-15	Sloan-Kettering Institute For Cancer Research	Uses of monoclonal antibody 8H9
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US6586251B2 (en)	2000-10-31	2003-07-01	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US7105348B2 (en)	2000-10-31	2006-09-12	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
IL155977A0 (en)	2000-11-30	2003-12-23	Medarex Inc	Transgenic transchromosomal rodents for making human antibodies
FR2817875B1 (fr)	2000-12-07	2005-03-18	Technopharm	Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
CA2474172C (en)	2001-01-25	2012-07-10	Evolva Ltd.	A library of a collection of cells
EP1395669B1 (en)	2001-01-26	2009-07-22	Selexis S.A.	Matrix attachment regions and methods for use thereof
WO2002096948A2 (en)	2001-01-29	2002-12-05	Idec Pharmaceuticals Corporation	Engineered tetravalent antibodies and methods of use
WO2002076196A1 (en)	2001-03-22	2002-10-03	Abbott Gmbh & Co. Kg	Transgenic animals expressing antibodies specific for genes of interest and uses thereof
GB0110029D0 (en)	2001-04-24	2001-06-13	Grosveld Frank	Transgenic animal
US7595378B2 (en) *	2001-06-13	2009-09-29	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2002100348A2 (en) *	2001-06-13	2002-12-19	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (egfr)
DK1402025T3 (da)	2001-06-15	2006-06-06	Crucell Holland Bv	Kimære fager
AU2002319402B2 (en)	2001-06-28	2008-09-11	Domantis Limited	Dual-specific ligand and its use
EP1806407B1 (en)	2001-07-04	2010-05-05	Chromagenics B.V.	DNA sequences having anti-repressor activity
CA2457362C (en)	2001-08-21	2012-01-17	Thomas Jefferson University	Human monoclonal rabies virus neutralizing antibodies, and methods for making and using the same
CN100513414C (zh)	2001-08-27	2009-07-15	杰南技术公司	进行抗体表达和装配的系统
DE60230918D1 (de)	2001-11-16	2009-03-05	Biogen Idec Inc	Polycistronische expression von antikörpern in cho zellen
WO2003046560A2 (en)	2001-11-30	2003-06-05	National Research Council Of Canada	Self-assembly molecules
AU2002363861A1 (en)	2001-11-30	2003-06-10	Crucell Holland B.V.	Antigen presenting cell targeting conjugate, an intigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
US20030215914A1 (en)	2001-12-10	2003-11-20	Erwin Houtzager	Structure for presenting desired peptide sequences
US20050037427A1 (en)	2001-12-10	2005-02-17	Erwin Houtzager	Structure for presenting desired peptide sequences
US7244592B2 (en) *	2002-03-07	2007-07-17	Dyax Corp.	Ligand screening and discovery
GB2387030A (en)	2002-03-26	2003-10-01	Thales Plc	Compensation of mutual coupling in array antenna systems
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
ITGE20020049A1 (it)	2002-06-05	2003-12-05	Ali Spa	Dispositivo a pistone per la erogazione di quantitativi dosati di sostanze pastose, quali i gelati, applicabile alle macchine per la loro fa
EP1513936A2 (en)	2002-06-14	2005-03-16	Chromagenics B.V.	Use of repression blocking sequences in methods for enhancing gene expression
DK1513937T3 (da)	2002-06-14	2011-05-16	Chromagenics Bv	Fremgangsmåde til den samtidige produktion af multiple proteiner; vektorer og celler til anvendelse derved
AU2002368062A1 (en)	2002-06-26	2004-01-19	Imclone Systems Incorporated	Bispecific antibodies that bind to vegf receptors
US20080241166A1 (en)	2002-06-28	2008-10-02	Domantis Limited	Ligands that bind a receptor
WO2004007860A1 (fr)	2002-07-10	2004-01-22	Agostino Di Trapani	Element de construction
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
EP2314629B2 (en) *	2002-07-18	2022-11-16	Merus N.V.	Recombinant production of mixtures of antibodies
CA2512647C (en)	2003-01-07	2013-10-08	Symphogen A/S	Method for manufacturing recombinant polyclonal proteins
EP1439234A1 (en)	2003-01-08	2004-07-21	ARTEMIS Pharmaceuticals GmbH	Targeted transgenesis using the rosa26 locus
WO2004106375A1 (en)	2003-05-30	2004-12-09	Merus Biopharmaceuticals B.V. I.O.	Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
AU2004245429A1 (en)	2003-06-10	2004-12-16	Farallone Holding Bv	Binding peptides: methods for their generation and use
SG128680A1 (en)	2003-07-22	2007-01-30	Crucell Holland Bv	Binding molecules against sars-coronavirus and uses thereof
ES2378767T3 (es)	2003-12-23	2012-04-17	Crucell Holland B.V.	Molécula de unión humana contra CD1a
AU2005205412B2 (en)	2004-01-20	2011-08-11	Merus N.V.	Mixtures of binding proteins
WO2005118644A2 (en)	2004-05-27	2005-12-15	Crucell Holland B.V.	Binding molecules capable of neutralizing rabies virus and uses thereof
MXPA06014075A (es)	2004-06-03	2007-03-15	Novimmune Sa	Anticuerpos anti-cd3 y metodos de uso de los mismos.
CA2577082A1 (en)	2004-09-02	2006-03-16	Genentech, Inc.	Heteromultimeric molecules
JP4487068B2 (ja)	2004-10-12	2010-06-23	国立大学法人岡山大学	細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
WO2006040322A1 (en)	2004-10-12	2006-04-20	Crucell Holland B.V.	Binding molecules for treatment and detection of cancer
KR101255861B1 (ko)	2004-11-11	2013-04-17	크루셀 홀란드 비.브이.	사스-코로나바이러스에 대한 조성물 및 그것의 용도
CN101198698B (zh)	2005-03-31	2014-03-19	中外制药株式会社	通过调节多肽缔合制备多肽的方法
JP2008538912A (ja)	2005-04-29	2008-11-13	イナート・ファルマ	遺伝子導入動物および組換え抗体の製造方法
WO2006120230A2 (en)	2005-05-12	2006-11-16	Crucell Holland B.V.	Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1893645A1 (en)	2005-06-23	2008-03-05	Crucell Holland B.V.	Optimization of west nile virus antibodies
CA2622603C (en)	2005-09-15	2014-06-17	Crucell Holland B.V.	Method for preparing immunoglobulin libraries
WO2007110205A2 (en)	2006-03-24	2007-10-04	Merck Patent Gmbh	Engineered heterodimeric protein domains
JP5514539B2 (ja)	2006-03-31	2014-06-04	メダレックス・リミテッド・ライアビリティ・カンパニー	ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
NZ587107A (en)	2006-06-02	2012-05-25	Regeneron Pharma	High affinity antibodies to human il-6 receptor
CN103351435B (zh)	2006-06-06	2015-08-19	克鲁塞尔荷兰公司	具有杀灭葡萄球菌活性的人结合分子及其应用
MX2008014978A (es)	2006-06-06	2008-12-09	Crucell Holland Bv	Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
WO2007147901A1 (en)	2006-06-22	2007-12-27	Novo Nordisk A/S	Production of bispecific antibodies
EP2059532B1 (en)	2006-09-07	2012-12-26	Crucell Holland B.V.	Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
LT2769992T (lt)	2006-10-02	2021-04-12	Regeneron Pharmaceuticals, Inc.	Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
US8290739B2 (en)	2006-10-20	2012-10-16	Amfit, Inc.	Method for determining relative mobility of regions of an object
RU2448979C2 (ru)	2006-12-14	2012-04-27	Ридженерон Фармасьютикалз, Инк.	Антитела человека к дельта-подобному лиганду-4 человека
CN104497143B (zh)	2007-03-29	2020-08-25	健玛保	双特异性抗体及其制造方法
ITMI20071522A1 (it)	2007-07-27	2009-01-28	Areta Internat S R L	Vaccino idiotipico
EP3124497B1 (en)	2007-09-14	2020-04-15	Adimab, LLC	Rationally designed, synthetic antibody libraries and uses therefor
US8536310B2 (en)	2007-10-17	2013-09-17	Arca Biopharma, Inc.	Antibodies to CLL-1
US8242247B2 (en)	2007-12-21	2012-08-14	Hoffmann-La Roche Inc.	Bivalent, bispecific antibodies
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
EP3663318A1 (en)	2008-01-07	2020-06-10	Amgen Inc.	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CA2715043C (en)	2008-02-05	2021-02-16	Zymeworks Inc.	Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
RU2731084C2 (ru)	2008-06-27	2020-08-28	Мерюс Н.В.	Продуцирующие антитела млекопитающие, не являющиеся человеком
EP2389392A1 (en)	2009-01-26	2011-11-30	Genmab A/S	Methods for producing mixtures of antibodies
AU2010245011B2 (en)	2009-04-27	2015-09-03	Oncomed Pharmaceuticals, Inc.	Method for making heteromultimeric molecules
MX2011011331A (es)	2009-05-11	2011-11-18	Crucell Holland Bv	Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas.
LT2975051T (lt)	2009-06-26	2021-07-12	Regeneron Pharmaceuticals, Inc.	Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
WO2011028952A1 (en)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
HRP20151188T4 (hr)	2010-02-08	2021-10-01	Regeneron Pharmaceuticals, Inc.	Miš sa zajedničkim lakim lancem
US20120021409A1 (en)	2010-02-08	2012-01-26	Regeneron Pharmaceuticals, Inc.	Common Light Chain Mouse
EP2569337A1 (en)	2010-05-14	2013-03-20	Rinat Neuroscience Corp.	Heterodimeric proteins and methods for producing and purifying them
EP2603526A1 (en)	2010-08-13	2013-06-19	Medimmune Limited	Monomeric polypeptides comprising variant fc regions and methods of use
AU2011290480B2 (en)	2010-08-16	2015-07-30	Novimmune S.A.	Methods for the generation of multispecific and multivalent antibodies
PL2635607T3 (pl)	2010-11-05	2020-05-18	Zymeworks Inc.	Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
LT2738259T (lt)	2011-02-25	2020-03-10	Regeneron Pharmaceuticals, Inc.	Adam6 pelės
AU2012235758B2 (en)	2011-03-25	2015-05-07	IGI Therapeutics SA	Hetero-dimeric immunoglobulins
JP2013004215A (ja)	2011-06-14	2013-01-07	Hitachi Ltd	リチウムイオン二次電池
JP2016184957A (ja)	2012-02-09	2016-10-20	シャープ株式会社	情報処理装置及び情報処理方法
DK2838918T3 (da)	2012-04-20	2019-08-12	Merus Nv	Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
PL2900694T3 (pl)	2012-09-27	2018-12-31	Merus N.V.	Dwuswoiste przeciwciała igg jako aktywatory komórek t

2003
- 2003-07-15 EP EP10186063.3A patent/EP2314629B2/en not_active Expired - Lifetime
- 2003-07-15 CN CN200910132819.2A patent/CN101537180B/zh not_active Expired - Lifetime
- 2003-07-15 JP JP2004522465A patent/JP4836451B2/ja not_active Expired - Lifetime
- 2003-07-15 NZ NZ537277A patent/NZ537277A/en not_active IP Right Cessation
- 2003-07-15 ES ES03764997T patent/ES2368733T3/es not_active Expired - Lifetime
- 2003-07-15 AT AT03764997T patent/ATE514717T1/de active
- 2003-07-15 CA CA2965865A patent/CA2965865C/en not_active Expired - Lifetime
- 2003-07-15 PT PT03764997T patent/PT1523496E/pt unknown
- 2003-07-15 CN CNB038170779A patent/CN100480260C/zh not_active Expired - Lifetime
- 2003-07-15 PT PT101860633T patent/PT2314629E/pt unknown
- 2003-07-15 SI SI200332045T patent/SI1523496T1/sl unknown
- 2003-07-15 CA CA2872136A patent/CA2872136C/en not_active Expired - Lifetime
- 2003-07-15 EP EP03764997A patent/EP1523496B1/en not_active Expired - Lifetime
- 2003-07-15 DK DK03764997.7T patent/DK1523496T3/da active
- 2003-07-15 AU AU2003250074A patent/AU2003250074B2/en not_active Expired
- 2003-07-15 CN CN201610051739.4A patent/CN105884893A/zh active Pending
- 2003-07-15 ES ES10186063T patent/ES2442615T5/es not_active Expired - Lifetime
- 2003-07-15 DK DK10186063.3T patent/DK2314629T4/da active
- 2003-07-15 WO PCT/EP2003/007690 patent/WO2004009618A2/en not_active Ceased
- 2003-07-15 CA CA2492377A patent/CA2492377C/en not_active Expired - Lifetime
2005
- 2005-01-18 US US11/039,767 patent/US7262028B2/en not_active Expired - Lifetime
2006
- 2006-11-06 US US11/593,279 patent/US7429486B2/en not_active Expired - Lifetime
- 2006-11-06 US US11/593,280 patent/US7932360B2/en not_active Expired - Lifetime
2008
- 2008-07-29 US US12/221,021 patent/US7927834B2/en not_active Expired - Lifetime
2010
- 2010-12-02 AU AU2010249150A patent/AU2010249150B9/en not_active Expired
2011
- 2011-03-04 US US12/932,719 patent/US9303081B2/en not_active Expired - Lifetime
- 2011-05-30 JP JP2011121054A patent/JP6049239B2/ja not_active Expired - Lifetime
- 2011-09-23 CY CY20111100924T patent/CY1111886T1/el unknown
2013
- 2013-03-12 US US13/795,637 patent/US20130243773A1/en not_active Abandoned
2014
- 2014-07-03 JP JP2014137927A patent/JP6166693B2/ja not_active Expired - Fee Related
2016
- 2016-04-04 US US15/090,505 patent/US10934571B2/en not_active Expired - Fee Related
- 2016-09-21 JP JP2016184803A patent/JP2016220696A/ja active Pending
2017
- 2017-12-14 US US15/842,303 patent/US20180094289A1/en not_active Abandoned
- 2017-12-27 US US15/855,258 patent/US20180112247A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1523496A2 (en)	2005-04-20
CN101537180B (zh)	2016-02-10
JP6166693B2 (ja)	2017-07-19
CN1668636A (zh)	2005-09-14
CA2965865A1 (en)	2004-01-29
US9303081B2 (en)	2016-04-05
EP2314629B2 (en)	2022-11-16
DK1523496T3 (da)	2011-10-17
US20130243773A1 (en)	2013-09-19
CY1111886T1 (el)	2015-11-04
US20180112247A1 (en)	2018-04-26
CA2492377A1 (en)	2004-01-29
US20110177073A1 (en)	2011-07-21
ES2442615T3 (es)	2014-02-12
NZ537277A (en)	2008-04-30
JP2016220696A (ja)	2016-12-28
CA2492377C (en)	2015-02-03
US7262028B2 (en)	2007-08-28
US7429486B2 (en)	2008-09-30
US20050170398A1 (en)	2005-08-04
EP1523496B1 (en)	2011-06-29
PT2314629E (pt)	2014-01-22
US20070054362A1 (en)	2007-03-08
US7927834B2 (en)	2011-04-19
AU2003250074B2 (en)	2010-09-09
AU2010249150B9 (en)	2013-12-19
AU2010249150B2 (en)	2012-10-04
WO2004009618A2 (en)	2004-01-29
WO2004009618A3 (en)	2004-11-04
CA2872136A1 (en)	2004-01-29
CA2965865C (en)	2021-10-19
SI1523496T1 (sl)	2011-11-30
AU2010249150A1 (en)	2010-12-23
EP2314629B1 (en)	2013-10-16
DK2314629T3 (da)	2014-01-20
CN101537180A (zh)	2009-09-23
PT1523496E (pt)	2011-09-29
CN105884893A (zh)	2016-08-24
US20180094289A1 (en)	2018-04-05
EP2314629A1 (en)	2011-04-27
HK1070902A1 (en)	2005-06-30
CN100480260C (zh)	2009-04-22
US10934571B2 (en)	2021-03-02
US20160319320A1 (en)	2016-11-03
JP2006515503A (ja)	2006-06-01
ES2368733T3 (es)	2011-11-21
CA2872136C (en)	2017-06-20
AU2003250074A1 (en)	2004-02-09
ATE514717T1 (de)	2011-07-15
JP2011177193A (ja)	2011-09-15
ES2442615T5 (es)	2023-03-16
US7932360B2 (en)	2011-04-26
US20070077624A1 (en)	2007-04-05
JP6049239B2 (ja)	2016-12-21
JP2014204734A (ja)	2014-10-30
JP4836451B2 (ja)	2011-12-14
US20090263864A1 (en)	2009-10-22

Publication	Publication Date	Title
ATE514717T1 (de)	2011-07-15	Rekombinante produktion von antikörpermischungen
DE60239823D1 (de)	2011-06-01	Exprimierungskontrolle unter verwendung von variabelen intergenischen sequenzen
ATE446972T1 (de)	2009-11-15	Il-1 bindende antikörper und fragmente davon
ATE497984T1 (de)	2011-02-15	Dimercaptanterminierte polythioetherpolymere und verfahren zu ihrer herstellung und verwendung
WO2002016436A3 (en)	2002-06-20	ANTIBODIES TO HUMAN IL-1$g(b)
ATE490787T1 (de)	2010-12-15	Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
DK1450847T3 (da)	2010-12-13	Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
WO2006113546A3 (en)	2009-04-30	Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
WO2011022077A3 (en)	2011-04-14	A nucleic acid cassette for producing recombinant antibodies
CY1111750T1 (el)	2015-10-07	Νευροτροφικοι παραγοντες
EA200700876A1 (ru)	2007-10-26	Агенты, специфически связывающие ангиопоэтин-2
DE60235588D1 (de)	2010-04-15	Monoklonales Antikörper gegen das HCV Kernantigen
WO2003016501A3 (en)	2005-03-24	Recombinant antibodies, and compositions and methods for making and using the same
WO2005047325A3 (en)	2005-07-28	Monkey immunoglobulin sequences
WO2006013462A3 (en)	2006-12-28	Growth factors nsg28, nsg30, and nsg32
DE60326716D1 (de)	2009-04-30	Promoter Sequenzen aus Moos und dessen Verwendung